Investor Presentaiton

Investor presentation First three months of 2017 Slide 8 Global roll-out of TresibaⓇ continuing according to plan supported by XultophyⓇ launches TresibaⓇ value share of basal insulin segment in selected countries, excluding the USA Switzerland Japan Mexico Combined value share of TresibaⓇ and XultophyⓇ in selected countries Switzerland Sweden Greece ■■■■■■ TresibaⓇ value share 40% 30% 20% 10% 0% 10 Netherlands Spain Denmark UK Sweden Brazil India Greece Italy 60% 50% 40% 40% 30% 28% 26% 25% 30% 20% 17% 18% 20% 11% 13% 10% 10% 5% 0% 20 30 40 10 Note: Limited IMS coverage in India Months from launch Source: IMS Monthly value figures, February 2017 changing diabetes® 20 30 55% 38% Months from TresibaⓇ launch Source: IMS Monthly value figures, February 2017 40 20% novo nordisk

View entire presentation